Literature DB >> 28360585

Syndrome of Headache Accompanied with Transient Neurologic Deficits and Cerebrospinal Fluid Lymphocytosis.

Arzu Çoban1, Erkingül Shugaiv1, Erdem Tüzün2.   

Abstract

The syndrome of headache accompanied with transient neurologic deficits and cerebrospinal fluid lymphocytosis (HaNDL), is a rare, benign and self limiting syndrome. In the 2nd Edition of the International Classification of Headache Disorders, HaNDL syndrome was defined in secondary headache group as "Headache attributed to non-vascular intracranial disorder". The etiology of HaNDL is still unknown. In recent years, some authors have shown that ion channel autoimmunity might at least partially contribute to HaNDL pathogenesis. In this paper, the definition of HaNDL syndrome, clinical picture and epidemiology of HaNDL syndrome, etiopathogenesis, differential diagnosis and treatment will be reviewed with the recent literature.

Entities:  

Keywords:  Headache; cerebrospinal fluid lymphocytosis; transient neurologic deficits

Year:  2013        PMID: 28360585      PMCID: PMC5353079          DOI: 10.4274/npa.y7228

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  29 in total

1.  Lack of visual evoked potential habituation in the syndrome of HaNDL.

Authors:  E Anagnostou; K Spengos; D Naoumis; G P Paraskevas; S Vassilopoulou; V Zis; D Vassilopoulos
Journal:  J Neurol       Date:  2009-04-12       Impact factor: 4.849

2.  Acute perfusion MR imaging in a HaNDL-like syndrome.

Authors:  Anne-Evelyne Vallet; Virginie Desestret; Florence Tahon; Tae-Hee Cho; Norbert Nighoghossian
Journal:  Cerebrovasc Dis       Date:  2009-11-19       Impact factor: 2.762

3.  Diffusion restriction in the splenium of the corpus callosum in a patient with the syndrome of transient headache with neurological deficits and CSF lymphocytosis (HaNDL): a challenge to the diagnostic criteria?

Authors:  Ivan Raets
Journal:  Acta Neurol Belg       Date:  2012-02-03       Impact factor: 2.396

4.  Migraine with tardy pleocytosis.

Authors:  C T Walter; W A Grogan
Journal:  Neurology       Date:  1986-05       Impact factor: 9.910

5.  Usefulness of multimodal MR imaging in the differential diagnosis of HaNDL and acute ischemic stroke.

Authors:  Tomas Segura; Francisco Hernandez-Fernandez; Pedro Sanchez-Ayaso; Elena Lozano; Lorenzo Abad
Journal:  BMC Neurol       Date:  2010-12-02       Impact factor: 2.474

6.  Pseudomigraine with temporary neurological symptoms and lymphocytic pleocytosis. A report of 50 cases.

Authors:  F Gómez-Aranda; F Cañadillas; J F Martí-Massó; E Díez-Tejedor; P J Serrano; R Leira; M Gracia; J Pascual
Journal:  Brain       Date:  1997-07       Impact factor: 13.501

7.  Ophthalmologic involvement in the syndrome of headache, neurologic deficits, and cerebrospinal fluid lymphocytosis.

Authors:  David G Morrison; Huan K Phuah; Alyssa T Reddy; Leon S Dure; Lanning B Kline
Journal:  Ophthalmology       Date:  2003-01       Impact factor: 12.079

8.  The transient syndrome of headache with neurological deficits, cerebrospinal fluid pleocytosis and acute confusional state: a case report.

Authors:  A Giorgetti; G Mariani; G M Patruno; A Romorini
Journal:  J Headache Pain       Date:  2005-12       Impact factor: 7.277

9.  Anti-neuronal antibodies associated with headache with neurological deficits and cerebrospinal fluid lymphocytosis.

Authors:  Murat Kürtüncü; Erdem Tüzün; Dilaver Kaya; Sema Içöz; M Bariş Baslo; Mustafa Ertaş; Gülşen Akman-Demir; Mefküre Eraksoy
Journal:  J Headache Pain       Date:  2008-08-12       Impact factor: 7.277

10.  Reversible cerebral vasoconstriction syndrome: an important cause of acute severe headache.

Authors:  Li Huey Tan; Oliver Flower
Journal:  Emerg Med Int       Date:  2012-07-09       Impact factor: 1.112

View more
  1 in total

1.  A rare neurologic deficiency in HaNDL syndrome: cranial neuropathy.

Authors:  Dilcan Kotan; Saadet Sayan; Semra Alacam Koksal
Journal:  Arch Med Sci Atheroscler Dis       Date:  2016-06-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.